Traders should monitor upcoming clinical milestones: readout from the CLBP Phase 3 trial later this year, initiation of the DMD registrational trial, and site activation in the adult SR-aGvHD study. The CAR technology acquisition could enhance product potency and create long-term value, but near-term revenue will be driven by Ryoncil® adoption.
MESO drugs
MESO drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 8 $13.92entry
- T+1 · 7mo ago +4.53%α +3.95% · $14.55
- T+5 · 7mo ago +13.15%α +9.63% · $15.75
- T+20 · 7mo ago +13.43%α +4.89% · $15.79
- T+60 · 4mo ago +3.30%α −7.15% · $14.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mesoblast highlighted its commercial strategy as Ryoncil® nears $100M in net revenue since launch, announced the close of enrollment in its Phase 3 trial for chronic low back pain (CLBP), received FDA clearance for a registrational trial in pediatric Duchenne muscular dystrophy (DMD), and acquired a patented CAR technology platform from Mayo Clinic to enhance its MSC therapies. The updates were shared during its R&D Day webcast.
Key Financial Metrics
Key Facts
- Ryoncil® is approaching $100 million in net revenue since its launch last year.
- Enrollment in the Phase 3 trial for chronic low back pain (CLBP) is closing at the end of the month.
- FDA cleared an IND to proceed directly to a registrational trial for Ryoncil® in pediatric DMD.
- Central IRB approval obtained for adult SR-aGvHD trial; first sites to activate this quarter.
- Acquired a patented CAR technology platform from Mayo Clinic to enhance MSC-based therapies.
Financial Impact
Ryoncil® nearing $100M in net revenue indicates growing commercial traction; DMD and CLBP programs represent significant future revenue potential.
Risk Factors
- Clinical trial setbacks in CLBP, DMD, or SR-aGvHD could delay approvals.
- Regulatory delays or rejections despite IND clearance.
- Forward-looking statements carry uncertainty; actual results may differ materially.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270209 |
Track record
25 reports on MESO
6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers